Clinical development company Curasight A/S (Spotlight:CURAS) announced on Friday that it has entered a clinical supply agreement with Curium for non-carrier-added Lutetium-177 to support its uTREAT platform.

Curium's irradiation network and large-scale manufacturing capacity, including its Petten facility, will meet key needs for uTREAT Phase III trials and commercialization in the US and Europe. Growing interest from major pharmaceutical firms in radiopharmaceuticals for cancer diagnosis and treatment underscores the strategic importance of securing access to these radiometals.

The agreement strengthens Curasight's position in the competitive radiopharmaceutical market. uTREAT is part of Curasight's uPAR theranostic solution, which combines the uTRACE diagnostic and uTREAT treatment technologies. uTRACE has been tested in multiple Phase II trials and aims to enhance cancer visualization for more personalized treatment. Curasight retains full development and commercialization rights for uTREAT across all indications.